<DOC>
	<DOCNO>NCT00071487</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy 3 different dos belimumab , administer addition standard therapy , patient active SLE disease .</brief_summary>
	<brief_title>Safety Efficacy Study LymphoStat-B ( Belimumab ) Subjects With Systemic Lupus Erythematosus ( SLE )</brief_title>
	<detailed_description>The purpose study evaluate safety efficacy three different dos belimumab ( 1 mg/kg , 4 mg/kg , 10 mg/kg ) , administer addition standard therapy , compare placebo plus standard therapy patient active SLE disease . Patients randomly assign , follow stratification screen SELENA SLEDAI score ( 4 7 versus ≥ 8 ) , 1 4 study arm ( 3 active arm 1 placebo arm plus standard therapy SLE ) . All patient dose Days 0 , 14 , 28 , every 28 day remainder 52 week . Patients complete 52-week period could enter 24-week open-label extension ; belimumab patient receive dose switch 10 mg/kg investigator 's discretion former placebo patient receive belimumab 10 mg/kg .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>Primary Inclusion Criteria Clinical diagnosis SLE `` Active '' SLE disease On stable SLE treatment regimen History measurable autoantibody Primary Exclusion Criteria Received nonFDA approve investigational agent within last 28 day Cyclosporin , intravenous immunoglobulin ( IVIG ) plasmapheresis within last 90 day Active lupus nephritis require hemodialysis , cyclophosphamide ( Cytoxan™ ) , highdose prednisone ( &gt; 100 mg/day ) within last 90 day Active central nervous system ( CNS ) lupus require therapeutic intervention within last 60 day History renal transplant History chronic infection active within last 6 month , herpes zoster within last 90 day infection require hospitalization intravenous medication within last 60 day History hypogammaglobulinemia immunoglobulin A ( IgA ) deficiency Human immunodeficiency virus ( HIV ) , Hepatitis B , Hepatitis C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>SLE</keyword>
</DOC>